Monograph Details
|
|
Eye Disorders
> Ocular allergy/inflammation
|
|
LOTEMAX |
| Manufacturer |
|
Bausch & Lomb Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Steroid. |
| Generic Name |
|
Loteprednol etabonate 0.5%; oph susp; contains benzalkonium chloride. |
| Indications |
|
Steroid-responsive ocular diseases. Post-op inflammation after ocular surgery. |
| Children |
|
Not recommended. |
| Adults |
|
Steroid-responsive diseases: 1–2 drops into affected eye(s) 4 times daily. May give up to 1 drop every 1 hr within the 1st week of therapy. Post-op: 1–2 drops into operated eye(s) 4 times daily beginning 24 hrs after surgery, continue for 2 wks post-op. |
| Contraindications |
|
Ocular fungal, viral, or mycobacterial infections. |
| Precautions |
|
Reevaluate if no improvement after 2 days. Prescribe initially and renew after 14 days only after appropriate exam. Corneal or scleral thinning. Glaucoma. History of herpes simplex. Monitor IOP and for secondary infections in prolonged therapy (>10 days). Avoid abrupt cessation. Soft contact lenses (remove during therapy). Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Local reactions (e.g., blurred vision, burning, itching, dry eye), photophobia, headache, rhinitis, pharyngitis. May mask or exacerbate ocular infections. Prolonged use may increase: IOP, optic nerve damage, visual acuity and field defects, cataract formation, corneal perforation. May delay healing and increase bleb formation after cataract surgery. |
| How Supplied |
|
Susp— 2.5mL, 5mL, 10mL, 15mL |
|
|
|
|
